Summit Partners Public Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Summit Partners Public Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-998,252	Closed	-$14.9M	–	128
2025 Q3	$14.9M	Buy	+998,252	New	+$12.2M	0.31%	87
2021 Q2	–	Sell	-115,072	Closed	-$4.63M	–	110
2021 Q1	$4.63M	Sell	115,072 -203,086	-64%	-$11M	0.2%	78
2020 Q4	$18.8M	Sell	318,158 -521,346	-62%	-$26.9M	0.84%	42
2020 Q3	$40.8M	Buy	839,504 +589,563	+236%	+$24.8M	2.04%	13
2020 Q2	$12.1M	Buy	249,941 +32,499	+15%	+$1.18M	0.72%	47
2020 Q1	$6.04M	Buy	+217,442	New	+$6.07M	0.5%	54

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Summit Partners Public Asset Management's ADPT Position: Q4 2025 in Review

Summit Partners Public Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 998,252 shares — an estimated $14.9M sold.

Summit Partners Public Asset Management first reported a position in ADPT in Q1 2020 and held it in 6 quarters. The position peaked at $40.8M in Q3 2020. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Summit Partners Public Asset Management reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Summit Partners Public Asset Management sold 998,252 Adaptive Biotechnologies shares in Q4 2025, an estimated $14.9M.
Summit Partners Public Asset Management first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 6 quarters.
Summit Partners Public Asset Management's Adaptive Biotechnologies position peaked at $40.8M in Q3 2020.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.